Improve the treatment available to people with grade 3–4 IDH-mutant glioma.
morca.bio is a mission, not a single product. Today we pursue it with engineered bacteria that ignite the immune system inside the tumor — but the mission is the fixed point. The tool is not.
A mission-driven hub, not a single-asset company.
morca.bio exists to advance treatment for one disease: grade 3–4 IDH-mutant glioma. We run our own programs, and we support and partner on others' — academic labs, CROs, and ventures working the same problem from different angles.
That makes us a hub, not a walled single-asset shop. There may be one track pursued at a time, or several, depending on what the science calls for and where the best work is happening.
A young person's cancer that always comes back.
Grade 3–4 IDH-mutant astrocytoma — the secondary-glioblastoma lineage — typically strikes people in their 30s and 40s. Maximal safe surgery, radiation, and chemotherapy buy time. None of it stops the tumor from returning.
Vorasidenib, the approved IDH inhibitor, blocks new production of the tumor's oncometabolite D-2-HG — it's approved in grade 2 disease and in an ongoing Phase 2 trial for grade 3. But grade 3–4 is a harder problem: D-2-HG is only one of several immunosuppressive mechanisms this tumor uses, so blocking its production alone is less of a complete answer. That gap — a harder disease, a margin nothing can reach — is what this mission targets.
Run what we can. Support what we can't.
Collaborative by design — working with academic groups and CROs, not building a walled single-asset company.
Run
We run our own programs end to end, from mechanism design through preclinical validation, in the open.
Support
We back and partner on programs led by others — academic labs, CROs, and ventures — when their work advances the same mission.
Share
Every program, ours or a partner's, feeds back into what we know about this disease and where the mission should point next.
Bacteria-leaning. Mission-fixed.
Right now, our conviction is engineered bacteria — living, programmable vehicles that can be built to survive only where the tumor is, carry more than one therapeutic payload, and ignite the immune system exactly where surgery and drugs can't reach: the tumor's infiltrating margin.
That's a present conviction, not a rule. The fixed point is the patients — people with grade 3–4 IDH-mutant glioma — not the tool. If a different modality serves the mission better, we'll pursue that instead.
This is early-stage science, built on a testable hypothesis and pursued rigorously — not a product available today.
However you come to this, there's a way to help.
Patients and families, clinicians, scientists and collaborators, supporters and funders — the mission needs all of it.